CRISPR Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

BRSE:1CG Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Feb 25BuyCHF 280,541John GreeneIndividual7,000CHF 40.08
19 Feb 25SellCHF 254,084Samarth KulkarniIndividual5,318CHF 47.78

Insider Trading Volume

Insider Buying: 1CG insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 1CG?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders384,5800.448%
General Public22,761,75326.5%
Institutions62,628,14173%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 59.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.7%
Capital Research and Management Company
9,185,813CHF 344.8m9.98%0.02%
10.5%
ARK Investment Management LLC
8,973,063CHF 336.8m19.7%3.42%
4.47%
T. Rowe Price Group, Inc.
3,836,271CHF 144.0m38.9%0.01%
3.22%
BlackRock, Inc.
2,759,326CHF 103.6m-1.29%no data
3.2%
Nikko Asset Management Co., Ltd.
2,745,676CHF 103.0m-53.7%0.04%
3.12%
UBS Asset Management AG
2,674,181CHF 100.4m98.1%0.01%
2.9%
State Street Global Advisors, Inc.
2,491,525CHF 93.5m-16.8%no data
2.59%
FMR LLC
2,223,262CHF 83.4m-6.43%0.01%
2.02%
The Vanguard Group, Inc.
1,735,998CHF 65.2m0.61%no data
1.85%
New Enterprise Associates, Inc.
1,587,854CHF 59.6m0%3.62%
1.72%
Orbis Investment Management Limited
1,476,119CHF 55.4m0%0.2%
1.62%
EcoR1 Capital, LLC
1,389,276CHF 52.1m0%2.88%
1.52%
Baker Bros. Advisors LP
1,308,011CHF 49.1m55.2%0.53%
1.22%
SR One Capital Management, LP
1,048,951CHF 39.4m0%10.75%
1.17%
Geode Capital Management, LLC
1,000,868CHF 37.6m-0.73%no data
1.1%
Dimensional Fund Advisors LP
947,301CHF 35.6m14.9%0.01%
1.06%
Loomis Sayles & Company, L.P.
910,965CHF 34.2m-3.63%0.05%
1.04%
Balyasny Asset Management L.P.
893,935CHF 33.6m43.3%0.09%
1.02%
Citadel Advisors LLC
878,896CHF 33.0m69.5%0.04%
0.84%
Charles Schwab Investment Management, Inc.
723,032CHF 27.1m-0.17%no data
0.83%
Bank of America Corporation, Asset Management Arm
715,626CHF 26.9m41.9%0.01%
0.58%
Versant Venture Management, LLC
498,558CHF 18.7m0%9.7%
0.55%
Morgan Stanley, Investment Banking and Brokerage Investments
475,454CHF 17.8m-19.6%no data
0.52%
Norges Bank Investment Management
443,536CHF 16.6m-31.8%no data
0.5%
Jane Street Group, LLC, Asset Management Arm
426,817CHF 16.0m149%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 04:00
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 44 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research